Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 94

1.

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.

Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, Danese S, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Bazan V, Amaducci L, Moretti G, Foschini MP, Balduzzi S, Vicini R, D'Amico R, Griguolo G, Guarneri V, Conte PF.

BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z.

2.

Potent cell cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, Phase 2 neoadjuvant study in HR+/HER2- breast cancer.

Hurvitz SA, Martín M, Press MF, Chan D, Fernandez-Abad M, Petru E, Rostorfer R, Guarneri V, Huang CS, Barriga S, Wijayawardana SR, Brahmachary M, Ebert PJ, Hossain A, Liu J, Abel A, Aggarwal A, Jansen VM, Slamon DJ.

Clin Cancer Res. 2019 Oct 15. pii: clincanres.1425.2019. doi: 10.1158/1078-0432.CCR-19-1425. [Epub ahead of print]

PMID:
31615937
3.

BRCA1/2 Molecular Assay for Ovarian Cancer Patients: A Survey through Italian Departments of Oncology and Molecular and Genomic Diagnostic Laboratories.

Capoluongo E, La Verde N, Barberis M, Bella MA, Buttitta F, Carrera P, Colombo N, Cortesi L, Gion M, Guarneri V, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A, Gori S.

Diagnostics (Basel). 2019 Oct 9;9(4). pii: E146. doi: 10.3390/diagnostics9040146.

4.

Myelopoiesis, metabolism and therapy: a crucial crossroads in cancer progression.

Sica A, Guarneri V, Gennari A.

Cell Stress. 2019 Jul 1;3(9):284-294. doi: 10.15698/cst2019.09.197. Review.

5.

Programmed Cell Death Ligand 1 in Breast Cancer: Technical Aspects, Prognostic Implications, and Predictive Value.

Miglietta F, Griguolo G, Guarneri V, Dieci MV.

Oncologist. 2019 Nov;24(11):e1055-e1069. doi: 10.1634/theoncologist.2019-0197. Epub 2019 Aug 23. Review.

6.

BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis.

Vernaci G, Dieci MV, Manfrin S, Mantiero M, Falci C, Faggioni G, Mioranza E, Menichetti A, Tasca G, Griguolo G, Miglietta F, Di Liso E, Saibene T, Michieletto S, Ghiotto C, Conte P, Guarneri V.

Breast. 2019 Oct;47:77-84. doi: 10.1016/j.breast.2019.07.003. Epub 2019 Jul 20. No abstract available.

PMID:
31357134
7.

Androgen Receptor Expression and Association With Distant Disease-Free Survival in Triple Negative Breast Cancer: Analysis of 263 Patients Treated With Standard Therapy for Stage I-III Disease.

Dieci MV, Tsvetkova V, Griguolo G, Miglietta F, Mantiero M, Tasca G, Cumerlato E, Giorgi CA, Giarratano T, Faggioni G, Falci C, Vernaci G, Menichetti A, Mioranza E, Di Liso E, Frezzini S, Saibene T, Orvieto E, Guarneri V.

Front Oncol. 2019 Jun 6;9:452. doi: 10.3389/fonc.2019.00452. eCollection 2019.

8.

Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

Gori S, Barberis M, Bella MA, Buttitta F, Capoluongo E, Carrera P, Colombo N, Cortesi L, Genuardi M, Gion M, Guarneri V, Incorvaia L, La Verde N, Lorusso D, Marchetti A, Marchetti P, Normanno N, Pasini B, Pensabene M, Pignata S, Radice P, Ricevuto E, Sapino A, Tagliaferri P, Tassone P, Trevisiol C, Truini M, Varesco L, Russo A; AIOM-SIGU-SIBIOC-SIAPEC-IAP Working Group.

Crit Rev Oncol Hematol. 2019 Aug;140:67-72. doi: 10.1016/j.critrevonc.2019.05.012. Epub 2019 May 25.

9.

Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.

Dieci MV, Guarneri V, Zustovich F, Mion M, Morandi P, Bria E, Merlini L, Bullian P, Oliani C, Gori S, Giarratano T, Orvieto E, Griguolo G, Michieletto S, Saibene T, Del Bianco P, De Salvo GL, Conte P; Veneto Oncology Network.

Oncologist. 2019 Nov;24(11):1424-1431. doi: 10.1634/theoncologist.2019-0103. Epub 2019 May 31.

PMID:
31152079
10.

HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade.

Prat A, Pascual T, De Angelis C, Gutierrez C, Llombart-Cussac A, Wang T, Cortés J, Rexer B, Paré L, Forero A, Wolff AC, Morales S, Adamo B, Brasó-Maristany F, Vidal M, Veeraraghavan J, Krop I, Galván P, Pavlick AC, Bermejo B, Izquierdo M, Rodrik-Outmezguine V, Reis-Filho JS, Hilsenbeck SG, Oliveira M, Dieci MV, Griguolo G, Fasani R, Nuciforo P, Parker JS, Conte P, Schiff R, Guarneri V, Osborne CK, Rimawi MF.

J Natl Cancer Inst. 2019 Apr 30. pii: djz042. doi: 10.1093/jnci/djz042. [Epub ahead of print]

PMID:
31037288
11.

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.

Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.

Oncologist. 2019 Aug;24(8):1128-1136. doi: 10.1634/theoncologist.2018-0563. Epub 2019 Apr 23.

PMID:
31015312
12.

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer.

Griguolo G, Pascual T, Dieci MV, Guarneri V, Prat A.

J Immunother Cancer. 2019 Mar 29;7(1):90. doi: 10.1186/s40425-019-0548-6. Review.

13.

Neoplastic Pericardial Effusion: A Monocentric Retrospective Study.

Di Liso E, Menichetti A, Dieci MV, Ghiotto C, Banzato A, Bianchi A, Pintacuda G, Padovan M, Nappo F, Cumerlato E, Miglietta F, Mioranza E, Zago G, Corti L, Guarneri V, Conte P.

J Palliat Med. 2019 Jun;22(6):691-695. doi: 10.1089/jpm.2018.0491. Epub 2019 Mar 19.

PMID:
30888908
14.

From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study).

Pasello G, Vicario G, Zustovich F, Oniga F, Gori S, Rosetti F, Bonetti A, Favaretto A, Toso S, Redelotti R, Santo A, Bernardi D, Giovanis P, Oliani C, Calvetti L, Gatti C, Palazzolo G, Baretta Z, Bortolami A, Bonanno L, Basso M, Menis J, Corte DD, Frega S, Guarneri V, Conte P; Veneto Oncology Network.

Oncologist. 2019 Jun;24(6):e318-e326. doi: 10.1634/theoncologist.2018-0712. Epub 2019 Mar 7.

PMID:
30846513
15.

Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.

Gadducci A, Guarneri V, Peccatori FA, Ronzino G, Scandurra G, Zamagni C, Zola P, Salutari V.

J Ovarian Res. 2019 Jan 28;12(1):9. doi: 10.1186/s13048-019-0484-6. Review.

16.

Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy.

Bonanno L, Pavan A, Attili I, Pasello G, Guarneri V.

J Thorac Oncol. 2019 Jan;14(1):e5-e7. doi: 10.1016/j.jtho.2018.08.2033. No abstract available.

PMID:
30579553
17.

Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary.

Giarratano T, Miglietta F, Giorgi CA, Tsvetkova V, Michieletto S, Evangelista L, Polico I, Dieci MV, Guarneri V.

Front Oncol. 2018 Dec 3;8:581. doi: 10.3389/fonc.2018.00581. eCollection 2018.

18.

Escalation and de-escalation in HER2 positive early breast cancer.

Dieci MV, Vernaci G, Guarneri V.

Curr Opin Oncol. 2019 Jan;31(1):35-42. doi: 10.1097/CCO.0000000000000492.

PMID:
30325338
19.

An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.

Pelizzari G, Arpino G, Biganzoli L, Cinieri S, De Laurentiis M, Del Mastro L, Di Leo A, Gori S, Guarneri V, Marchetti P, Puglisi F.

BMC Cancer. 2018 Sep 27;18(1):932. doi: 10.1186/s12885-018-4843-2.

20.

Clinicopathological and Treatment-Associated Prognostic Factors in Patients with Breast Cancer Leptomeningeal Metastases in Relation to Tumor Biology.

Griguolo G, Pouderoux S, Dieci MV, Jacot W, Bourgier C, Miglietta F, Firmin N, Conte P, Viala M, Guarneri V, Darlix A.

Oncologist. 2018 Nov;23(11):1289-1299. doi: 10.1634/theoncologist.2018-0200. Epub 2018 Aug 17.

Supplemental Content

Loading ...
Support Center